Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma – Bristol-Myers Squibb Company (NYSE: BMY) announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Mayo researchers: Dramatic outcomes in prostate cancer study – Success with ipilimumab or MDX-010 in prostate cancer patients – Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.
FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer — Second melanoma drug approved this year that improves overall survival – The U.S. Food and Drug Administration recently approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
